Published in Clinical Oncology Week, April 4th, 2005
"The acute and cumulative dose-related toxicity and drug resistance, mediated via nuclear factor kappa B (NFkappaB), of anthracycline anticancer drugs pose a major problem in cancer chemotherapy," according to scientists in the United States.
"Here, we report that oral silibinin (a flavanone) suppresses human non-small-cell lung carcinoma A549 xenograft growth (p=0.003) and enhances the therapeutic response (p<0.05) of doxorubicin in athymic BALB/c nu/nu...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.